Neutral Recommendation Issued On IDYA By Goldman Sachs
Source: KlickAnalytics
2025-10-21 09:15:09 ET
Historical Analyst Recommendations
Latest 10 recommendationsFull story available on KlickAnalytics.com
IDEAYA Biosciences Inc.
NASDAQ: IDYA
IDYA Trading
-1.52% G/L:
$32.48 Last:
170,945 Volume:
$33.22 Open:
IDYA Latest News
March 09, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
February 25, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 23, 2026 06:00:00 am
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDYA Stock Data
$2,916,661,394
85,474,748
1.71%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
